73 related articles for article (PubMed ID: 22731611)
1. NGF/γ-IFN inhibits androgen-independent prostate cancer and reverses androgen receptor function through downregulation of FGFR2 and decrease in cancer stem cells.
Chen W; Wang GM; Guo JM; Sun LA; Wang H
Stem Cells Dev; 2012 Dec; 21(18):3372-80. PubMed ID: 22731611
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
3. Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145.
Sigala S; Tognazzi N; Rizzetti MC; Faraoni I; Missale C; Bonmassar E; Spano P
Eur J Endocrinol; 2002 Sep; 147(3):407-15. PubMed ID: 12213679
[TBL] [Abstract][Full Text] [Related]
4. Paired box 2 upregulates androgen receptor gene expression in androgen-independent prostate cancer.
Ito S; Ueda T; Ueno A; Nakagawa H; Taniguchi H; Hongo F; Kamoi K; Okihara K; Kawauchi A; Miki T
FEBS J; 2014 Oct; 281(19):4506-18. PubMed ID: 25132193
[TBL] [Abstract][Full Text] [Related]
5. [Neuronal differentiation and TrkA expression of neuroblastoma induced by the combination treatment of interferon-gamma and NGF].
Wang H; Zhang JH; Mi Z
Zhonghua Er Ke Za Zhi; 2004 Mar; 42(3):180-3. PubMed ID: 15144710
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells.
Cronauer MV; Nessler-Menardi C; Klocker H; Maly K; Hobisch A; Bartsch G; Culig Z
Br J Cancer; 2000 Jan; 82(1):39-45. PubMed ID: 10638964
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
10. Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
Neschadim A; Pritzker LB; Pritzker KP; Branch DR; Summerlee AJ; Trachtenberg J; Silvertown JD
Endocr Relat Cancer; 2014 Jun; 21(3):459-71. PubMed ID: 24812057
[TBL] [Abstract][Full Text] [Related]
11. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
13. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells.
Basrawala Z; Alimirah F; Xin H; Mohideen N; Campbell SC; Flanigan RC; Choubey D
Oncogene; 2006 May; 25(19):2812-7. PubMed ID: 16331249
[TBL] [Abstract][Full Text] [Related]
15. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
16. Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: role of the high- and low-affinity NGF receptors.
Sortino MA; Condorelli F; Vancheri C; Chiarenza A; Bernardini R; Consoli U; Canonico PL
Mol Endocrinol; 2000 Jan; 14(1):124-36. PubMed ID: 10628752
[TBL] [Abstract][Full Text] [Related]
17. The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator.
Dotan N; Wasser SP; Mahajna J
Integr Cancer Ther; 2011 Jun; 10(2):148-59. PubMed ID: 21147815
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling.
Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Takeuchi S; Koeffler HP; Taguchi H
Cancer Sci; 2005 Jul; 96(7):425-33. PubMed ID: 16053514
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
20. Effect of aberrantly methylated androgen receptor target gene PCDH7 on the development of androgen-independent prostate cancer cells.
Xu S; Wu X; Tao Z; Li H; Fan C; Chen S; Guo J; Ning Y; Hu X
Genes Genomics; 2020 Mar; 42(3):299-307. PubMed ID: 31872382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]